Hepatitis C News

Among patients treated with sofosbuvir and velpatasvir for hepatitis C virus, the minimal monitoring approach achieved sustained virological response similar to standard monitoring, according to research.

Novel hepatitis B virus RNA and HBV core-related antigen blood assays revealed continued disease activity despite apparently suppressed virus replication among patients dosed with antiviral therapy for HBV and HIV coinfection.

Simplifying the hepatitis C virus treatment process is essential to improving care among vulnerable populations, particularly people who inject drugs.

Compared with the general population, adults on probation are disproportionately impacted by hepatitis C, but they rarely receive care, complete treatment or achieve viral suppression, according to a study.

Hepatitis D, in hepatitis B surface antigen-positive individuals, may remain undiagnosed due to lack of testing, particularly in primary care settings, according to a poster.

Onsite screening with a fingerstick assay at addiction treatment centers increased diagnosis and treatment of hepatitis C among people who use drugs, researchers reported.

Game-changing therapies have made the WHO goal of achieving hepatitis C elimination by 2030 possible, but many countries find themselves fighting an uphill battle, according to experts.

Hepatitis C testing has increased in recent years among people who are incarcerated in provincial correctional centers in British Columbia, Canada, according to new data.

New data suggest that failure to achieve sustained virologic response after treatment with direct-acting antivirals for hepatitis C was a strong predictor for development of hepatocellular carcinoma.

Patients with hepatitis C virus have always carried an increased risk for developing hepatocellular carcinoma. Although antiviral treatment for HCV reduces that risk, it is not eliminated.